探究卵巢癌铂类耐药性：机制、靶点及临床意义

Ovarian cancer is a common malignant tumor, and platinum-based drugs are currently the first-line drugs used for the treatment of ovarian cancer. However, with the widespread use of platinum-based drugs, the incidence of platinum resistance has gradually increased. According to statistics, approximately 30-50% of ovarian cancer patients develop resistance to platinum-based drugs after treatment. Therefore, it becomes particularly important to explore the platinum resistance in ovarian cancer, as understanding the mechanisms of platinum resistance can help us better understand the occurrence and development process of ovarian cancer.

Currently, the formation of platinum resistance is believed to involve multiple factors, including the cell's DNA repair ability, cell apoptosis pathway, and expression of transport proteins. Through in-depth research on these mechanisms, important evidence can be provided for finding new treatment strategies. The occurrence of platinum resistance is often related to the abnormal activation of intracellular signaling pathways, and exploring platinum resistance in ovarian cancer is beneficial for identifying new therapeutic targets and drugs.

In addition, understanding the situation of platinum resistance in ovarian cancer is beneficial for the clinical development of individualized treatment plans. Different patients have varying degrees of resistance to platinum-based drugs. Therefore, understanding the patient's resistance situation can help doctors choose more appropriate treatment plans and improve the treatment effectiveness.